| Budget Amount *help |
¥46,020,000 (Direct Cost: ¥35,400,000、Indirect Cost: ¥10,620,000)
Fiscal Year 2013: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
Fiscal Year 2012: ¥9,620,000 (Direct Cost: ¥7,400,000、Indirect Cost: ¥2,220,000)
Fiscal Year 2011: ¥9,620,000 (Direct Cost: ¥7,400,000、Indirect Cost: ¥2,220,000)
Fiscal Year 2010: ¥10,010,000 (Direct Cost: ¥7,700,000、Indirect Cost: ¥2,310,000)
Fiscal Year 2009: ¥10,660,000 (Direct Cost: ¥8,200,000、Indirect Cost: ¥2,460,000)
|
|---|
| Research Abstract |
Aggregation of the 42-mer amyloid beta peptide (Abeta42) plays a critical role in the pathogenesis of Alzheimer's disease (AD). We have recently identified the toxic turn at Glu-22 and Asp-23 of Abeta42. Based on the toxic turn, we developed a new antibody 11A1 that selectively recognized the toxic trimer as well as the intracellular Abeta which could not be detected by commercially available Abeta antibodies. Therefore, 11A1 might become a diagnostic drug for AD. By contrast, we found that catechol-type flavonoids could specifically suppress Abeta42 aggregation by targeting the Lys-residues.
|
